Mankind Pharma Ltd
NSE: MANKIND BSE: 543904
₹2240.10
(0.11%)
Fri, 20 Mar 2026, 07:48 am
Market Cap923.78B
PE Ratio52.03
Dividend0.04
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1991
- The company was incorporated as a private limited company under the Companies Act, 1956, with the name Mankind Pharma Private Limited on July 3
2004
- Entered the chronic pharmaceutical segment with the launch of Amlokind tablets and Glimestar tablets amongst others
2005
- The name of the company was changed to Mankind Pharma Limited
- Set up the first manufacturing facility at Paonta Sahib, Himachal Pradesh
- Entered the ophthalmic pharmaceutical segment with the launch of Lubistar Eye Drops and Tobastar Eye Drops amongst others
2006
- The RoC issued a fresh certificate of incorporation on April 13
2007
- Entered the consumer healthcare segment with the launch of Manforce brand
- Entered the animal healthcare segment with launch of Bandykind and Ceftiforce amongst others
- Raised 720 million from Monet Limited
2009
- Set up a manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh
2010
- Launched Preganews brand in the consumer healthcare segment
2012
- Set up the first R&D centre at IMT Manesar, Haryana
2014
- Acquired Shree Jee Laboratory Private Limited along with its API manufacturing site situated at Behror, Rajasthan
- Set up a manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh
2015
- Incorporated Lifestar Pharma LLC in the US
- Incorporated Mankind Pharma Pte. Limited in Singapore
2017
- Set up a manufacturing facility in Sikkim
2018
- The manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time
2019
- Entered the female infertility segment with the launch of Dydroboon tablets
2020
- Incorporated Lifestar Pharmaceuticals Private Limited in Nepal
- Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of Cilaheart tablets and Statpure tablets
- Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of Zukanorm tablets
2021
- Incorporated Mankind Pharma FZ-LLC in Dubai, UAE
- Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of Mlife tablets
- Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of Trugaba-NT tablets and Prebris-MNT tablets
2022
- Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited
- Entered into transplant segment with the launch of Pangraf Capsules and Mycept tablets amongst others
- Entered into oncology segment with the launch of Pacliall injection amongst others
- Acquired the brands Daffy and Combihale from Dr. Reddy’s Laboratories
- Mankind Life Sciences Private Limited acquired 90.00% of the issued, subscribed and paid-up share capital of Upakarma Ayurveda Private Limited.
2023
- Mankind Pharma Sets New Industry Standard with Unprecedented Display on Burj Khalifa, Reinforcing Commitment to Excellence.
- Mankind Pharma announced its partnership with SpiceJet to raise awareness about DMF-grade API.
- Mankind Pharma Product Prega News and Sonam Kapoor partners to transform from pregnancy detection card to pregnancy care solution.
2024
- Mankind Pharma Completes Landmark Acquisition of BSV.
- Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab.
- Mankind Pharma Launches 45-Day Healthcare Mission at Mahakumbh Serving Thousands of Pilgrims with Free Health Check-ups.
- Mankind Pharma Product Healthok has joined hands with Bikanervala.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800